A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China

The effectiveness of sugemalimab vs. placebo in post-chemoradiotherapy patients with locally advanced, unresectable stage III NSCLC has been demonstrated and approved by China National Medical Products Administration. The purpose of this study was to assess the cost-effectiveness of sugemalimab vs....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2023-06, Vol.18 (6), p.e0286595-e0286595
Hauptverfasser:	Li, Wei, Wan, Li
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Biology and Life Sciences Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Care and treatment Chemoradiotherapy Chemotherapy Clinical medicine Clinical trials Comorbidity Consolidation Cost analysis Cost-Benefit Analysis Costs Database industry Diagnosis Discounts Economic aspects Effectiveness End of life GDP Gems Gross Domestic Product Health care Health services Humans Immunotherapy Lung cancer Lung cancer, Non-small cell Lung Neoplasms - drug therapy Maintenance Markov chains Markov processes Medical care, Cost of Medical electronics Medical equipment Medical prognosis Medicine and Health Sciences Modelling Non-small cell lung carcinoma Parameter sensitivity Patient outcomes Patients People and Places Placebos Product development Radiation therapy Radiotherapy Research and Analysis Methods Sensitivity analysis Social Sciences Software Survival Therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!